Skip to main content

Advertisement

Fig. 4 | Molecular Cancer

Fig. 4

From: Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma

Fig. 4

a SLC6A3 expression was determined using immunohistochemistry in renal tissues; a representative image showing SLC6A3 immunohistochemical staining in ccRCC and normal renal tissue is shown. b The Boxplot diagram demonstrates the distribution of SLC6A3 expression in renal tissues: Nuclear, cytoplasmic and especially luminal-membranous SLC6A3 expression was high in proximal tubules (PT), whereas it was moderate in the distal tubules (DT) and clear cell renal cell carcinoma tissue (ccRCC); it was only weakly expressed in the loop of Henle (LoH). c SLC6A3 expression in tumor cells was predictive for progression-free survival: the period of progression-free survival was shorter in patients with SLC6A3 levels above the mean as shown in the Kaplan Meier estimates

Back to article page